Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Table 4 Drugs which were used in the 1st line

EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV, cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin; TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001, everolimus

ISSN: 1471-2407